Antileukemic activity of glycated fibrinogen-methotrexate conjugates

Anticancer Research

Volumn 25, Issue 3 B, 2005, Pages 2229-2234

  Kanska, Urszula ^a   Omar, Mohamed Salah ^a   Budzynska, Renata ^a   Nevozhay, Dmitry ^a   Jagiello, Monika ^a   Opolski, Adam ^a,b   Boratynski, Janusz ^a,b  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b JAN DLUGOSZ UNIVERSITY   (Poland)

Author keywords

Antitumor activity; Conjugates; Fibrinogen; Glycation; Methotrexate

Indexed keywords

DRUG CARRIER; FIBRINOGEN; GLUCOSE; METHOTREXATE; PLASMIN;

AMADORI REARRANGEMENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG CONJUGATION; GLYCATION; HIGH TEMPERATURE; LEUKEMIA; LEUKEMIA P 388; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; STATISTICAL ANALYSIS; SURVIVAL TIME;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; DISEASE MODELS, ANIMAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FIBRINOGEN; GLYCOSYLATION; HEAT; LEUKEMIA P388; METHOTREXATE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; PLASMIN;

EID: 21344462350     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Dvorak HF, Senger DR and Dvorak AM: Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metast Rev 2: 41-73, 1983.
2. Dvorak HF, Nagy JA, Berse B, Brown LF, Yeo KT, Yeo TK, Dvorak AM, van de Water L, Sioussat TM and Senger DR: Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation. Ann NY Acad Sci 667: 101-111, 1992.
3. Nagy JA, Brown LF, Senger DR, Lanir N, Van de Water L, Dvorak AM and Dvorak HF: Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim Biophys Acta 948: 305-326, 1989.
4. Boratynski J, Opolski A, Wietrzyk J, Gorski A and Radzikowski C: Cytotoxic and antitumor effect of fibrinogen-methotrexate conjugate. Cancer Lett 148: 189-195, 2000.
5. Hirakawa W, Kadota K, Asakura T, Niiro M, Yokoyama S, Hirano H, Yatsushiro K, Kubota Y and Shimodozono Y: Local chemotherapy for malignant brain tumors using methotrexate-containing fibrin glue. Gan To Kagaku Ryoho 22: 805-809, 1995.
6. Reynolds KM: The chemistry of nonenzymatic browning. II. Adv Food Res 14: 167-283, 1965.
7. van Boekel MA: The role of glycation in aging and diabetes mellitus. Mol Biol Rep 15: 57-64, 1991.
8. Krantz S, Lober M, Thiele M and Teuscher E: Properties of in vitro nonenzymatically glycated plasma fibrinogens. Exp Clin Endocrinol 90: 37-45, 1987.
9. Murakami T, Egawa H, Komiyama Y, Masuda M and Murata K: Increased accumulation of nonenzymatically glycated fibrinogen in the renal cortex in rats. Thromb Res 58: 23-33, 1990.
10. Boratynski J: Dry reaction of proteins with carbohydrates at 120 °C yields neoglycoconjugates. Biotechnol Tech 12: 707-710, 1998.
11. Boratynski J and Roy R: High temperature conjugation of proteins with carbohydrates. Glycoconj J 15: 131-138, 1998.
12. Kanska U and Boratynski J: Thermal glycation of proteins by D-glucose and D-fructose. Arch Immunol Ther Exp 50: 61-66, 2002.
13. Stefanowicz P, Boratynski J, Kanska U, Petry I and Szewczuk Z: Evaluation of high temperature glycation of proteins and peptides by electrospray ionization mass spectrometry. Acta Biochim Pol 48: 1137-1141, 2001.
14. Cierniewski CS, Pluskota E, Cieslak M, Brodniewicz T and Nowotarski M: Antigenic properties of fibrinogen component of Hemaseel HMN subjected to the antiviral severe dry heat treatment. Thromb Res 82: 349-359, 1996.
15. Tuan T, Wu H, Huang EY, Chong SSN, Laug W, Messadi D, Kelly P and Le A: Increased plasminogen activator inhibitor-1 in keloid fibroblasts may account for their elevated collagen accumulation in fibrin gel cultures. Am J Pathol 162: 1579-1589, 2003.
16. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
17. NIH Publication: Experimental Therapeutics Program. In Vivo Cancer Models. Bethesda, MD, No. 84-2635, 1976-1982.
18. Khleif SN and Curt GA: Animal models in drug development. In: Cancer Medicine (Holland JF, Frei E, Bast Jr RC, Kufe DW, Morton DL, Weichselbaum RR, eds). London, Lea & Febiger, pp. 653-666, 1993.
19. Brownlee M, Vlassara H and Cerami A: Nonenzymatic glycosylation reduces the susceptibility of fibrin to degradation by plasmin. Diabetes 32: 680-684, 1983.
20. Jackson MR: Fibrin sealants in surgical practice: an overview. Am J Surg 182(2 Suppl): 1S-7S, 2001.
21. Martinowitz U and Saltz R: Fibrin sealant. Curr Opin Hematol 3: 395-402, 1996.
22. Kim IM, Lee CY, Son EI, Kim DW, Kim SP and Sohn CH: Merits of intralesional fibrin glue injection in surgery for cavernous sinus cavernous hemangiomas. Technical note. J Neurosurg 97: 718-721, 2002.